Literature DB >> 9886762

Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.

R Upton1, P S Widdowson, S Ishii, H Tanaka, G Williams.   

Abstract

1. We examined the effect of chronic (21 days) oral treatment with the thiazolidinedione, MCC-555 ((+)-5-[[6-(2-fluorbenzyl)-oxy-2-naphy]methyl]-2,4-thiazo lid inedione) on metabolic status and insulin sensitivity in obese (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats which display an impaired glucose tolerance (IGT) or overt diabetic symptoms, respectively. 2. MCC-555 treatment to obese Zucker rats (10 and 30 mg kg(-1)) and diabetic ZDF rats (10 mg kg(-1)) reduced non-esterified fatty acid concentrations in both rat strains and reduced plasma glucose and triglyceride concentrations in the obese Zucker rats. Liver glycogen concentrations were significantly increased by chronic MCC-555 treatment in both obese Zucker rats (30 mg kg(-1) day(-1)) and diabetic ZDF rats (10 mg kg(-1) day(-1)), as compared with vehicle-treated lean and obese rats and there was a significant increase in hepatic glycogen synthase activity in MCC-555-treated diabetic ZDF rats as compared to vehicle-treated controls. 3. During a euglycaemic hyperinsulinaemic clamp, MCC-555-treated obese Zucker rats and diabetic ZDF rats required significantly higher glucose infusion rates to maintain stable glucose concentrations (2.01+/-0.19 mg min(-1) and 6.42+/-1.03 mg min(-1), respectively) than vehicle-treated obese controls (0.71+/-0.17 mg min(-1) and 2.09+/-0.71 mg min(-1); P<0.05), demonstrating improved insulin sensitivity in both Zucker and ZDF rats. MCC-555 treatment also enhanced insulin-induced suppression of hepatic glucose production in ZDF rats as measured using infusions of [6-3H]-glucose under clamp conditions. 4. In conclusion, we have demonstrated that MCC-555 improves metabolic status and insulin sensitivity in obese Zucker and diabetic ZDF rats. MCC-555 may prove a useful compound for alleviating the metabolic disturbances and IGT associated with insulin resistance in man.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886762      PMCID: PMC1565756          DOI: 10.1038/sj.bjp.0702245

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.

Authors:  Oxana P Lazarenko; Sylwia O Rzonca; Larry J Suva; Beata Lecka-Czernik
Journal:  Bone       Date:  2005-08-30       Impact factor: 4.398

2.  A peroxisome proliferator-activated receptor ligand MCC-555 imparts anti-proliferative response in pancreatic cancer cells by PPARgamma-independent up-regulation of KLF4.

Authors:  Kyung-Won Min; Xiaobo Zhang; Temjenmongla Imchen; Seung Joon Baek
Journal:  Toxicol Appl Pharmacol       Date:  2012-06-30       Impact factor: 4.219

3.  Reversal of NAFLD After VSG Is Independent of Weight-Loss but RYGB Offers More Efficacy When Maintained on a High-Fat Diet.

Authors:  Ankita Srivastava; Matthew Stevenson; Jenny Lee; Christopher Hall; Thomas Palaia; Chaohui Lisa Zhao; Raymond Lau; Collin Brathwaite; Louis Ragolia
Journal:  Obes Surg       Date:  2022-04-14       Impact factor: 3.479

Review 4.  New pharmacologic agents for diabetes.

Authors:  C J Bailey
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

5.  Early exposure of the pregestational intrauterine and postnatal growth-restricted female offspring to a peroxisome proliferator-activated receptor-{gamma} agonist.

Authors:  Meena Garg; Manikkavasagar Thamotharan; Gerald Pan; Paul W N Lee; Sherin U Devaskar
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-15       Impact factor: 4.310

6.  Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat.

Authors:  Lucy C Pickavance; Peter S Widdowson; John R Foster; Gareth Williams; John P H Wilding
Journal:  Int J Exp Pathol       Date:  2003-04       Impact factor: 1.925

7.  Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects.

Authors:  Fang Zhang; Brian E Lavan; Francine M Gregoire
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

8.  Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zücker rats.

Authors:  Eduardo J Lezcano; Pablo Iñigo; Ana M Larraga; Cristina Barranquero; Ignacio Gimenez; Jesús Osada
Journal:  Diabetol Metab Syndr       Date:  2014-01-27       Impact factor: 3.320

9.  Rhodiola crenulata extract regulates hepatic glycogen and lipid metabolism via activation of the AMPK pathway.

Authors:  Kuen-Tze Lin; Shih-Wei Hsu; Feng-Yi Lai; Tsu-Chung Chang; Li-Shian Shi; Shih-Yu Lee
Journal:  BMC Complement Altern Med       Date:  2016-05-17       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.